Combining Immunotherapy and Chemotherapy for Non-Small Cell Lung Cancer

Research output: Contribution to journalReview articlepeer-review

36 Scopus citations

Abstract

Over the past year, the combination of platinum-based chemotherapy and immunotherapy has become the standard of care for patients with metastatic non-small-cell lung cancer with any programmed death ligand 1 tumor proportion score. There is preclinical evidence demonstrating potential synergistic immunomodulation with combination therapy by enhancing immune-mediated tumor death and by disrupting the immunosuppressive tumor microenvironment that prevents immune detection. This potential synergy or complementary activity has been demonstrated in clinical trials showing improved and durable responses with chemo-immunotherapy.

Original languageEnglish
Pages (from-to)199-206
Number of pages8
JournalThoracic Surgery Clinics
Volume30
Issue number2
DOIs
StatePublished - May 1 2020

Keywords

  • Antineoplastic Agents/pharmacology
  • Carcinoma, Non-Small-Cell Lung/pathology
  • Combined Modality Therapy
  • Humans
  • Immunotherapy/methods
  • Lung Neoplasms/pathology
  • Molecular Targeted Therapy/methods
  • Programmed Cell Death 1 Receptor/antagonists & inhibitors

Fingerprint

Dive into the research topics of 'Combining Immunotherapy and Chemotherapy for Non-Small Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this